International investment firm CapVest Partners has officially announced the closing of its acquisition of a majority stake in STADA Arzneimittel AG. The transition under new investor control marks the beginning of a development stage for one of the largest pharmaceutical companies specializing in Consumer Healthcare, generics, and specialty pharmaceuticals.
Financial Performance as a Foundation
The change of primary ownership occurs against the backdrop of record financial results for STADA. For the 2025 financial year, the company’s revenue reached 4.3 billion euros, a 6% increase over the previous year. Adjusted EBITDA amounted to 961 million euros.
STADA’s headquarters are located in Bad Vilbel (Germany), with products sold in over 100 countries. The corporation’s global workforce counts nearly 11,700 employees. The company’s portfolio includes products such as the cold and flu remedy Grippostad®, the anti-dandruff shampoo Nizoral®, and the sleep improvement capsules Lunestil®.
Plans: Organic Growth and New M&A
The completion of regulatory procedures allows the combined CapVest and STADA team to proceed with implementing a strategy to accelerate global expansion. Development drivers will be investments in organic business growth and the pursuit of new strategic acquisitions in the international market.
“We are satisfied with the completion of the transaction. CapVest’s experience in the healthcare sector and support for our growth ambitions will be a significant advantage as we realize our business development plans.”
— Peter Goldschmidt, CEO of STADA
“During our work on the transaction, the STADA team continued to demonstrate confident growth in key regions and segments. We welcome the opportunity for active interaction with management to realize our common ambitious plans.”
— Matt Fargie, Partner at CapVest investment fund
CapVest’s Strategy: Betting on Resilient Sectors
The CapVest investment group specializes in investments in companies providing essential goods and services. The healthcare sector is key for the fund’s investments due to the high stability of demand.
The integration of CapVest’s resources and STADA’s business model is intended to strengthen the pharmaceutical manufacturer’s leadership positions on the global stage.
